Kadimastem Ltd. is developing innovative stem cell based therapeutics invented by Prof. Michel Revel at the Weizmann Institute. Prof. Revel currently serves as the Company's Chief Scientist. Kadimastem holds an exclusive license from Yeda Research and Development Co. Ltd. (the Technology Transfer Company of the Weizmann Institute of Science) regarding the commercialization of embryonic stem cells for the treatment of juvenile diabetes. The company is focusing on a technology for the transformation of human embryonic stem cells towards insulin secreting cells. These cells would be transplanted into Juvenile Diabetes patients for potential cure of the disease. Kadimastem is also developing an encapsulation technology to prevent the immunological destruction of the transplanted cells and also cell based assays for screening of lead compounds for the treatment of neurological disorders.
Visit http://www.kadimastem.com/ for more information.